GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » EV-to-FCF

Immunotech Biopharm (HKSE:06978) EV-to-FCF : -9.22 (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Immunotech Biopharm's Enterprise Value is HK$1,877.34 Mil. Immunotech Biopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-203.63 Mil. Therefore, Immunotech Biopharm's EV-to-FCF for today is -9.22.

The historical rank and industry rank for Immunotech Biopharm's EV-to-FCF or its related term are showing as below:

HKSE:06978' s EV-to-FCF Range Over the Past 10 Years
Min: -14.48   Med: 0   Max: 0
Current: -9.37

HKSE:06978's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 8.345 vs HKSE:06978: -9.37

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Immunotech Biopharm's stock price is HK$2.93. Immunotech Biopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.711. Therefore, Immunotech Biopharm's PE Ratio for today is At Loss.


Immunotech Biopharm EV-to-FCF Historical Data

The historical data trend for Immunotech Biopharm's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm EV-to-FCF Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -11.84 -15.68 -7.93 -14.13

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -15.68 - -7.93 - -14.13

Competitive Comparison of Immunotech Biopharm's EV-to-FCF

For the Biotechnology subindustry, Immunotech Biopharm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunotech Biopharm's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's EV-to-FCF falls into.



Immunotech Biopharm EV-to-FCF Calculation

Immunotech Biopharm's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1877.338/-203.627
=-9.22

Immunotech Biopharm's current Enterprise Value is HK$1,877.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immunotech Biopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-203.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunotech Biopharm  (HKSE:06978) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Immunotech Biopharm's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.93/-0.711
=At Loss

Immunotech Biopharm's share price for today is HK$2.93.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immunotech Biopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.711.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Immunotech Biopharm EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunotech Biopharm (HKSE:06978) Business Description

Traded in Other Exchanges
N/A
Address
No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Executives
Jung Hyun Chul
Evodevo Ltd
Tian Jin He Yue Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Wu Naifeng 2501 Other
Yan Kaijing 2501 Other
Yan Xijun 2501 Other
Tian Shi Li Kong Gu Ji Tuan You Xian Gong Si 2501 Other
Tian Shi Li Yi Yao Ji Tuan Gu Fen You Xian Gong Si 2501 Other
Tian Jin Di Zhi Tou Zi Guan Li You Xian Gong Si 2501 Other
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si 2501 Other
Li Yunhui 2501 Other
Tian Jin Hong Xun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Kang Shun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Shan Zhen Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Shun Qi Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other

Immunotech Biopharm (HKSE:06978) Headlines

No Headlines